What Happened? Shares of cannabis company Tilray Brands (NASDAQ:TLRY) fell 19.7% in the afternoon session after the company reported weak fiscal third-quarter 2025 results that missed analysts' sales and EBITDA estimates, signaling ongoing challenges in growing its top line. What stood out was the company's decision to scale back exposure to low-margin cannabis products and shift focus toward more profitable international markets. This choice, while aimed at improving margins, contributed to a double digit growth decline in cannabis revenue, making it harder to offset softness in other areas of the business. Looking ahead, the company cut its full-year revenue forecast, citing sales impact from its ongoing restructuring efforts. Overall, this was a weaker quarter, highlighting critical growth issues. The shares closed the day at $0.46, down 21.3% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tilray? Access our full analysis report here, it’s free. What The Market Is Telling Us Tilray’s shares are extremely volatile and have had 44 moves greater than 5% over the last year. But moves this big are rare even for Tilray and indicate this news significantly impacted the market’s perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock dropped 13.5% on the news that the company reported underwhelming fourth quarter results. Its revenue and EBITDA missed significantly, and its gross margin fell short of Wall Street's estimates. Also, the company recorded significant operating losses and continued to burn cash. On the other hand, revenue guidance for 2025 came in ahead of expectations, though sales partly benefited from recent acquisitions following the company's expansion to the beverage market, which suggested organic growth was not as strong. Zooming out, we think this was a mixed quarter. The market seemed to focus on the negatives, and the stock traded down. Tilray is down 68.9% since the beginning of the year, and at $0.45 per share, it is trading 82.5% below its 52-week high of $2.59 from April 2024. Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. View Comments
Why Tilray (TLRY) Stock Is Trading Lower Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...